Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
The FDA expanded the approved use of a therapy for metastasized breast cancer with a certain germline genetic mutation.
Elderly lung cancer patients who are black or from less educated communities are less likely to get the combination of chemotherapy and radiation that’s linked to better survival odds.
Two-year post-radiotherapy biopsies do not predict survival for most men with prostate cancer.
The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
Women with breast cancer often feel rushed to make a decision about surgery, and some of them might benefit from more time and better educational materials to inform their treatment choices.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
Patients with cancer treated through the Department of Veterans Affairs are less likely to receive excessive end-of-life interventions than patients treated through Medicare.
In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.